1887

Abstract

The C-terminal portion of the prion protein (PrP), corresponding to a protease-resistant core fragment of the abnormal isoform of the prion protein (PrP), is essential for prion propagation. Antibodies to the C-terminal portion of PrP are known to inhibit PrP accumulation in cells persistently infected with prions. Here it was shown that, in addition to monoclonal antibodies (mAbs) to the C-terminal portion of PrP, a mAb recognizing the octapeptide repeat region in the N-terminal part of PrP that is dispensable for PrP formation reduced PrP accumulation in cells persistently infected with prions. The 50 % effective dose was as low as ∼1 nM, and, regardless of their epitope specificity, the inhibitory mAbs shared the ability to bind cellular prion protein (PrP) expressed on the cell surface. Flow cytometric analysis revealed that mAbs that bound to the cell surface during cell culture were not internalized even after their withdrawal from the growth medium. Retention of the mAb–PrP complex on the cell surface was also confirmed by the fact that internalization was enhanced by treatment of cells with dextran sulfate. These results suggested that anti-PrP mAb antagonizes PrP formation by interfering with the regular PrP degradation pathway.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80113-0
2004-11-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/11/vir853473.html?itemId=/content/journal/jgv/10.1099/vir.0.80113-0&mimeType=html&fmt=ahah

References

  1. Borchelt D. R., Taraboulos A., Prusiner S. B. 1992; Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J Biol Chem 267:16188–16199
    [Google Scholar]
  2. Bueler H., Aguzzi A., Sailer A., Greiner R. A., Autenried P., Aguet M., Weissmann C. 1993; Mice devoid of PrP are resistant to scrapie. Cell 73:1339–1347 [CrossRef]
    [Google Scholar]
  3. Caughey B., Race R. E. 1992; Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem 59:768–771 [CrossRef]
    [Google Scholar]
  4. Caughey B., Raymond G. J. 1991; The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 266:18217–18223
    [Google Scholar]
  5. Caughey B., Raymond G. J. 1993; Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 67:643–650
    [Google Scholar]
  6. Caughey W. S., Raymond L. D., Horiuchi M., Caughey B. 1998; Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A 95:12117–12122 [CrossRef]
    [Google Scholar]
  7. Chabry J., Caughey B., Chesebro B. 1998; Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 273:13203–13207 [CrossRef]
    [Google Scholar]
  8. Chen S. G., Teplow D. B., Parchi P., Teller J. K., Gambetti P., Autilio-Gambetti L. 1995; Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem 270:19173–19180 [CrossRef]
    [Google Scholar]
  9. Demaimay R., Adjou K. T., Beringue V., Demart S., Lasmezas C. I., Deslys J. P., Seman M., Dormont D. 1997; Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J Virol 71:9685–9689
    [Google Scholar]
  10. Demaimay R., Race R., Chesebro B. 1999; Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons. J Virol 73:3511–3513
    [Google Scholar]
  11. Doh-Ura K., Iwaki T., Caughey B. 2000; Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74:4894–4897 [CrossRef]
    [Google Scholar]
  12. Doh-ura K., Ishikawa K., Murakami-Kubo I., Sasaki K., Mohri S., Race R., Iwaki T. 2004; Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78:4999–5006 [CrossRef]
    [Google Scholar]
  13. Ehlers B., Diringer H. 1984; Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 65:1325–1330 [CrossRef]
    [Google Scholar]
  14. Enari M., Flechsig E., Weissmann C. 2001; Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98:9295–9299 [CrossRef]
    [Google Scholar]
  15. Flechsig E., Shmerling D., Hegyi I., Raeber A. J., Fischer M., Cozzio A., von Mering C., Aguzzi A., Weissmann C. 2000; Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 27:399–408 [CrossRef]
    [Google Scholar]
  16. Gauczynski S., Peyrin J. M., Haik S. 8 other authors 2001; The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 20:5863–5875 [CrossRef]
    [Google Scholar]
  17. Gilch S., Wopfner F., Renner-Muller I., Kremmer E., Bauer C., Wolf E., Brem G., Groschup M. H., Schatzl H. M. 2003; Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem 278:18524–18531 [CrossRef]
    [Google Scholar]
  18. Heppner F. L., Prinz M., Aguzzi A. 2001; Pathogenesis of prion diseases: possible implications of microglial cells. Prog Brain Res 132:737–750
    [Google Scholar]
  19. Holscher C., Delius H., Burkle A. 1998; Overexpression of nonconvertible PrP c Δ114–121 in scrapie-infected mouse neuroblastoma cells leads to trans -dominant inhibition of wild-type PrP Sc accumulation. J Virol 72:1153–1159
    [Google Scholar]
  20. Horiuchi M., Caughey B. 1999; Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 18:3193–3203 [CrossRef]
    [Google Scholar]
  21. Horiuchi M., Priola S. A., Chabry J., Caughey B. 2000; Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A 97:5836–5841 [CrossRef]
    [Google Scholar]
  22. Ishiyama M., Tominaga H., Shiga M., Sasamoto K., Ohkura Y., Ueno K. 1996; A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19:1518–1520 [CrossRef]
    [Google Scholar]
  23. Kaneko K., Peretz D., Pan K. M. 7 other authors 1995; Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Sci U S A 92:11160–11164 [CrossRef]
    [Google Scholar]
  24. Kaneko K., Zulianello L., Scott M., Cooper C. M., Wallace A. C., James T. L., Cohen F. E., Prusiner S. B. 1997; Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci U S A 94:10069–10074 [CrossRef]
    [Google Scholar]
  25. Kim C.-L., Umetani A., Matsui T., Ishiguro N., Shinagawa M., Horiuchi M. 2004; Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology 320:40–51 [CrossRef]
    [Google Scholar]
  26. Korth C., May B. C., Cohen F. E., Prusiner S. B. 2001; Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98:9836–9841 [CrossRef]
    [Google Scholar]
  27. Ladogana A., Casaccia P., Ingrosso L., Cibati M., Salvatore M., Xi Y.-G., Masullo C., Pocchiari M. 1992; Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 73:661–665 [CrossRef]
    [Google Scholar]
  28. Lawson V. A., Priola S. A., Wehrly K., Chesebro B. 2001; N-terminal truncation of prion protein affects both formation and conformation of abnormal protease-resistant prion protein generated in vitro . J Biol Chem 276:35265–35271 [CrossRef]
    [Google Scholar]
  29. Leucht C., Simoneau S., Rey C., Vana K., Rieger R., Lasmezas C. I., Weiss S. 2003; The 37 kDa/67 kDa laminin receptor is required for PrPSc propagation in scrapie-infected neuronal cells. EMBO Rep 4:290–295 [CrossRef]
    [Google Scholar]
  30. Li R., Liu T., Wong B.-S. 7 other authors 2000; Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus. J Mol Biol 301:567–573 [CrossRef]
    [Google Scholar]
  31. Mallucci G., Dickinson A., Linehan J., Klohn P. C., Brandner S., Collinge J. 2003; Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302:871–874 [CrossRef]
    [Google Scholar]
  32. Mishra R. S., Gu Y., Bose S., Verghese S., Kalepu S., Singh N. 2002; Cell surface accumulation of a truncated transmembrane prion protein in Gerstmann–Straussler–Scheinker disease P102L. J Biol Chem 277:24554–24561 [CrossRef]
    [Google Scholar]
  33. Murakami-Kubo I., Doh-Ura K., Ishikawa K., Kawatake S., Sasaki K., Kira J., Ohta S., Iwaki T. 2004; Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol 78:1281–1288 [CrossRef]
    [Google Scholar]
  34. Naslavsky N., Stein R., Yanai A., Friedlander G., Taraboulos A. 1997; Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J Biol Chem 272:6324–6331 [CrossRef]
    [Google Scholar]
  35. Pan T., Wong B. S., Liu T., Li R., Petersen R. B., Sy M. S. 2002; Cell-surface prion protein interacts with glycosaminoglycans. Biochem J 368:81–90 [CrossRef]
    [Google Scholar]
  36. Peretz D., Williamson R. A., Kaneko K. 10 other authors 2001; Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412:739–743 [CrossRef]
    [Google Scholar]
  37. Perrier V., Solassol J., Crozet C., Frobert Y., Mourton-Gilles C., Grassi J., Lehmann S. 2004; Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 89:454–463 [CrossRef]
    [Google Scholar]
  38. Peters P. J., Mironov A. Jr, Peretz D. 8 other authors 2003; Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J Cell Biol 162:703–717 [CrossRef]
    [Google Scholar]
  39. Priola S. A., Raines A., Caughey W. S. 2000; Porphyrin and phthalocyanine antiscrapie compounds. Science 287:1503–1506 [CrossRef]
    [Google Scholar]
  40. Race R. E., Fadness L. H., Chesebro B. 1987; Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol 68:1391–1399 [CrossRef]
    [Google Scholar]
  41. Rogers M., Yehiely F., Scott M., Prusiner S. B. 1993; Conversion of truncated and elongated prion proteins into the scrapie isoform in cultured cells. Proc Natl Acad Sci U S A 90:3182–3186 [CrossRef]
    [Google Scholar]
  42. Shyng S. L., Heuser J. E., Harris D. A. 1994; A glycolipid-anchored prion protein is endocytosed via clathrin-coated pits. J Cell Biol 125:1239–1250 [CrossRef]
    [Google Scholar]
  43. Shyng S. L., Lehmann S., Moulder K. L., Harris D. A. 1995; Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem 270:30221–30229 [CrossRef]
    [Google Scholar]
  44. Sigurdsson E. M., Brown D. R., Daniels M., Kascsak R. J., Kascsak R., Carp R., Meeker H. C., Frangione B., Wisniewski T. 2002; Immunization delays the onset of prion disease in mice. Am J Pathol 161:13–17 [CrossRef]
    [Google Scholar]
  45. Solforosi L., Criado J. R., McGavern D. B. 12 other authors 2004; Cross-linking cellular prion protein triggers neuronal apoptosis in vivo . Science 303:1514–1516 [CrossRef]
    [Google Scholar]
  46. Soto C., Kascsak R. J., Saborio G. P. 10 other authors 2000; Reversion of prion protein conformational changes by synthetic β -sheet breaker peptides. Lancet 355:192–197 [CrossRef]
    [Google Scholar]
  47. Sunyach C., Jen A., Deng J., Fitzgerald K. T., Frobert Y., Grassi J., McCaffrey M. W., Morris R. 2003; The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein. EMBO J 22:3591–3601 [CrossRef]
    [Google Scholar]
  48. Supattapone S., Nguyen H.-O. B., Cohen F. E., Prusiner S. B., Scott M. R. 1999; Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 96:14529–14534 [CrossRef]
    [Google Scholar]
  49. Supattapone S., Wille H., Uyechi L., Safar J., Tremblay P., Szoka F. C., Cohen F. E., Prusiner S. B., Scott M. R. 2001; Branched polyamines cure prion-infected neuroblastoma cells. J Virol 75:3453–3461 [CrossRef]
    [Google Scholar]
  50. Vey M., Pilkuhn S., Wille H., Nixon R., DeArmond S. J., Smart E. J., Anderson R. G., Taraboulos A., Prusiner S. B. 1996; Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci U S A 93:14945–14949 [CrossRef]
    [Google Scholar]
  51. Weissmann C. 1999; Molecular genetics of transmissible spongiform encephalopathies. J Biol Chem 274:3–6 [CrossRef]
    [Google Scholar]
  52. White A. R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J., Hawke S. 2003; Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422:80–83 [CrossRef]
    [Google Scholar]
  53. Xi Y.-G., Ingrosso L., Ladogana A., Masullo C., Pocchiari M. 1992; Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature 356:598–601 [CrossRef]
    [Google Scholar]
  54. Zahn R., Liu A., Lührs T. 7 other authors 2000; NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A 97:145–150 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80113-0
Loading
/content/journal/jgv/10.1099/vir.0.80113-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error